SAN DIEGO, June 21 /PRNewswire/ -- Epimmune Inc. (Nasdaq: EPMN), a leader
in using gene maps of cancer-associated proteins and infectious agents to
design vaccines that induce cellular immunity, today announced that Dr. Emile
Loria, President and Chief Executive Officer of Epimmune, is scheduled to
present at the BIO 2001 International Investor and Partnering Forum.
The presentation is scheduled to take place on Tuesday, June 26, 2001 at
11:15 a.m. PT (2:15 p.m. ET) from the Convention Center in San Diego,
California.
During the presentation, Dr. Loria will provide an overview of Epimmune's
programs, business strategy, and recent developments. The Company's
presentation will be broadcast live via the Internet and can be accessed at:
http://www.informedinvestors.com/iif_forums/client_capsule.cfm?companyID=224
The webcast can also be accessed through a link on the Company's homepage
at http://www.epimmune.com. Following the live presentation, the webcast will
be archived for approximately one week and can be accessed at the above
referenced addresses.
Epimmune Inc. is a leader in using gene maps of cancer-associated proteins
and infectious agents to design vaccines that induce cellular immunity. The
Company's technology platform is based on its pioneering work in deciphering
the genetic code which regulates T-cell activation and in identifying antigen
fragments known as epitopes which can activate highly targeted T-cell
responses to tumors, viruses, bacteria and parasites. This new field of
pharmacology opens two new areas of pharmaceutical development: protective
vaccines that activate T-cell protection against infections, such as HIV and
hepatitis C, and therapeutic vaccines designed to stimulate antigen-specific
T-cell responses to infections, such as HIV, hepatitis C and hepatitis B, and
tumors such as breast, colon, lung and prostate. For more information on
Epimmune, visit http://www.epimmune.com.
This press release includes forward-looking statements that reflect
management's current views of future events, including the expectation of the
timing for commencement of clinical trials and anticipated trends in revenue
and operating expenses. Actual results may differ materially from the above
forward-looking statements due to a number of important factors, including but
not limited to the risks associated with the Company's ability to develop
vaccines using epitopes, the ability of epitope-based vaccines to control
infectious diseases and cancer, the safety and efficacy of epitope-based
vaccines in humans, the Company's ability to enter into and maintain new
collaborations, achievement of research and development objectives by the
Company and any collaborator, the timing and cost of conducting human clinical
trials, the regulatory approval process, and the possibility that testing may
reveal undesirable and unintended side effects or other characteristics that
may prevent or limit the commercial use of proposed products. These factors
are more fully discussed in the Company's 2000 Form 10-K, the most recent
10-Qs and other periodic reports filed with the Securities and Exchange
Commission.
SOURCE Epimmune Inc.
 back to top
Related links:
http://www.epimmune.com
CONTACT:
Robert De Vaere, VP, Finance and CFO of
Epimmune Inc., 858-860-2553; or Media, Laura Hansen of Susan E.
Atkins & Associates, 858-860-0266, for Epimmune Inc.
|
